BBIO PDUFA Date: Oral infigratinib Page updated November 5, 2026 · next FDA decision on the calendar · Data as of Nov 5, 2026 5:03 AM ET FDA decision (PDUFA) target Feb 4, 2027 · BridgeBio Pharma, Inc. · Children with achondroplasia
Key facts FDA PDUFA target date 2027-02-04
Drug / candidate Oral infigratinib
Indication Children with achondroplasia
Company BridgeBio Pharma, Inc.
Market-cap tier Large
New to FDA decisions? Read what a PDUFA date is and how often the FDA approves drugs .
See every 2027 PDUFA date → All February 2027 PDUFA dates → FAQ When is the BBIO PDUFA date? The FDA PDUFA target date for BBIO (BridgeBio Pharma, Inc.) is 2027-02-04 for Oral infigratinib. Dates are company/FDA-sourced and can slip. Verify against primary filings.
What is BBIO's drug Oral infigratinib? Oral infigratinib is BridgeBio Pharma, Inc.'s candidate under FDA review for Children with achondroplasia.
Not affiliated with or endorsed by the FDA. pdufa.bio is an independent publication with no affiliation with, endorsement by, sponsorship by, or connection to the U.S. Food and Drug Administration or any other government agency. “FDA”, “PDUFA” and all company, drug and ticker names are used descriptively and remain the property of their respective owners.Informational and educational purposes only. Not investment advice. Nothing on this page is investment, legal, tax or medical advice, or an offer or solicitation to buy or sell any security. pdufa.bio is not a registered investment adviser or broker-dealer and does not recommend trades or publish individual-drug approval probabilities. Verify every date and outcome against primary FDA, SEC or company filings. Data is provided as is, without warranty of any kind, and past behaviour does not predict future outcomes.